Sorafenib, a first-line therapeutic agent for the treatment of hepatocellular carcinoma, increases H3K27me3 levels in tumor cells and induces EZH2 activation after long-term treatment. This evidence concerns the gene EZH2 and hepatocellular carcinoma.